We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00115128
First Posted: June 22, 2005
Last Update Posted: May 13, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Amgen
  Purpose
The purpose of this study is to clinically evaluate the spleen during PBPC mobilization by filgrastim in normal donors.

Condition Intervention
Normal PBPC Donors Drug: filgrastim

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors

Resource links provided by NLM:


Further study details as provided by Amgen:

Primary Outcome Measures:
  • Spleen fold change measured by ultrasound [ Time Frame: Before, during, and through 1 week post-PBPC mobilization and collection ]

Secondary Outcome Measures:
  • Spleen change associations with filgrastim dose and hematologic variables [ Time Frame: Before, during, and through 1 week post-PBPC mobilization and collection ]

Biospecimen Retention:   None Retained
none collected

Enrollment: 309
Study Start Date: November 2003
Study Completion Date: September 2007
Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Filgrastim
Normal donors being treated with filgrastim for PBPC mobilization and collection
Drug: filgrastim
Normal donors being treated with filgrastim for PBPC mobilization and collection

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Normal donors
Criteria
Inclusion Criteria: - Eligible to be PBPC donor for allogeneic transplantation as determined by local institution Exclusion Criteria: - History of splenectomy - Previous PBPC mobilization attempts - Previous treatment with GCSF or GMCSF
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00115128


Sponsors and Collaborators
Amgen
Investigators
Study Director: MD Amgen
  More Information

Additional Information:
Publications:
Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT00115128     History of Changes
Obsolete Identifiers: NCT00108966
Other Study ID Numbers: 20020143
First Submitted: June 21, 2005
First Posted: June 22, 2005
Last Update Posted: May 13, 2013
Last Verified: May 2013

Keywords provided by Amgen:
normal PBPC donors

Additional relevant MeSH terms:
Lenograstim
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs